Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Classical hematology 1

Conditions

Neoplasms, Plasma Cell 1Lymphoma 1Leukemia 1Hematologic Neoplasms 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cyclophosphamide 227Cytarabine 194fludarabine phosphate 138Methotrexate 132Filgrastim 127Busulfan 103Etoposide 99Peripheral Blood Stem Cell Transplantation 91Rituximab 81fludarabine 77Radiotherapy 77Vincristine 74Daunorubicin 68Antilymphocyte Serum 65Cyclosporine 63Dexamethasone 61Tacrolimus 56Mycophenolic Acid 53Melphalan 52Imatinib Mesylate 50Granulocyte Colony-Stimulating Factor 50Mercaptopurine 46Whole-Body Irradiation 45Idarubicin 43sargramostim 42Methylprednisolone 42Doxorubicin 41Flow Cytometry 40Prednisone 39Clofarabine 39

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Leukemia × Glycopeptides × Clear all
NCT00195533 2009-11-16

Study Comparing Piperacillin-tazobactam Versus Piperacillin-tazobactam Plus Glycopeptide in Neutropenic Patients

Wyeth is now a wholly owned subsidiary of Pfizer

Completed
801 enrolled
Classical hematologyLymphoidOther hematologic neoplasmPlasma cell

Anemia, Refractory, with Excess of Blasts, Leukemia, Lymphoma, Hematologic Neoplasms, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡